Geode Capital Management LLC Purchases 79,488 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Geode Capital Management LLC increased its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 715,570 shares of the company's stock after buying an additional 79,488 shares during the quarter. Geode Capital Management LLC owned 0.20% of Bausch Health Companies worth $5,767,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in BHC. Mountain Hill Investment Partners Corp. bought a new stake in Bausch Health Companies in the fourth quarter valued at about $56,000. Tobam boosted its holdings in Bausch Health Companies by 10.4% in the fourth quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after acquiring an additional 1,422 shares during the last quarter. Norges Bank acquired a new stake in shares of Bausch Health Companies during the 4th quarter worth approximately $141,000. DGS Capital Management LLC acquired a new position in shares of Bausch Health Companies in the 4th quarter valued at $143,000. Finally, Kendall Capital Management increased its stake in Bausch Health Companies by 43.4% in the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after purchasing an additional 5,445 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BHC. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Royal Bank of Canada cut their target price on shares of Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a research note on Monday, April 7th. Finally, StockNews.com cut Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $7.17.

Bausch Health Companies Stock Performance

Shares of BHC stock traded up $0.09 on Tuesday, hitting $5.50. The company's stock had a trading volume of 1,104,255 shares, compared to its average volume of 2,697,242. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The stock's 50 day moving average is $6.21 and its 200-day moving average is $7.29. The company has a market capitalization of $2.03 billion, a PE ratio of -45.83, a PEG ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. On average, research analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.